LLY.US releases phase III data for three-target agonists

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that on September 30, LLY.US (LLY.US) announced the detailed results of the TRIUMPH-2 study. TRIUMPH-2 is a phase III clinical study to evaluate the efficacy and safety of retatrutide in obese or overweight adult patients with type 2 diabetes.

Retatrutide is a polypeptide drug developed by Eli Lilly based on the GIP peptide sequence that simultaneously targets glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and gastric suppressive peptide receptor (GIPR). The average half-life in humans is 6 days. Retatrutide is currently the fastest progressing GLP-1R/GIPR/GCGR agonist.

Eli Lilly plans to submit a biological product license application (BLA) to the US Food and Drug Administration (FDA) in the first quarter of 2027. Further findings from the obstructive sleep apnea trial in the TRIUMPH-2 study will be presented at future medical conferences and published in peer-reviewed journals.